Loading company…
Cambridge-based biotechnology company developing gene editing medicines for cardiovascular diseases.
Verve Therapeutics develops gene editing medicines for cardiovascular diseases. Its lead candidate, VERVE-101, is a single-course in vivo liver gene editing treatment for heterozygous familial hypercholesterolemia that targets the PCSK9 and ANGPTL3 genes. The company, founded in 2018 in Massachusetts, US, raised USD 63 million in Series A2 funding led by GV in 2020 and USD 94 million in Series B funding in 2021, then completed a USD 266.68 million IPO on Nasdaq in June 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in